GSK plc launches £20 billion Euro Medium Term Note programme
Pharmaceutical company GSK plc has established a £20 billion Euro Medium Term Note programme. The programme allows subsidiary entities to issue notes to fund their operations and general corporate purposes.
GSK plc, a global pharmaceutical company, has established a £20 billion Euro Medium Term Note (EMTN) programme. Under this programme, its subsidiary entities, including GlaxoSmithKline Capital plc, GSK Capital B.V., and GlaxoSmithKline Capital Inc., may from time to time issue notes to raise debt financing.
The maximum aggregate nominal amount of all notes that may be outstanding at any time under the programme will not exceed £20 billion, subject to increase. Notes may be issued in various currencies and will be offered on a continuous basis to one or more dealers appointed by the relevant issuer. This structure provides flexibility in managing the company's funding requirements.
Notes issued under the programme are intended to be admitted to trading on the International Securities Market (ISM) of the London Stock Exchange. The ISM is a market designed for professional investors and is not a regulated market under UK or EU financial services regulations. Pricing and terms for each issuance will be determined by the relevant issuer and dealers based on prevailing market conditions.
GSK plc acts as the guarantor for notes issued by its subsidiaries under this programme. The company's senior unsecured debt rating is currently A2 from Moody's, reflecting its financial standing.